Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease

N/AApproved For MarketingNCT01297933

Children's Hospital of Philadelphia

Overview

A compassionate use protocol to provide Omegaven to pediatric patients with parenteral nutrition (PN) dependence and parenteral nutrition associated liver disease (PNALD).

Omegaven is an intravenous fat emulsion (IFE) comprised of omega-3 fatty acids derived from fish oil. It will be used in an open label compassionate use treatment protocol, as an alternative to soybean oil (omega-6), as the sole IFE source of parenteral nutrition in an effort to reduce and/or reverse parenteral nutrition associated liver disease. The study will evaluate the safety and efficacy of Omegaven use in pediatric patients with PN dependence and PNALD.

Study Type

EXPANDED_ACCESS

Conditions

Cholestasis Short Bowel Syndrome

Interventions

OmegavenDRUG

10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.

Eligibility

Sex: ALLMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PN dependence due to congenital or acquired gastrointestinal disease * Predicted PN requirement for at least an additional 30 days * Parenteral nutrition associated liver disease (PNALD), defined as two conjugated bilirubin levels \>= 2 mg/dL at least one week apart, must be obtained to demonstrate persistence of PNALD * Failure to respond to standard therapies which may include cycling PN, reduction in the dose of soybean derived IFE, attempts to advance enteral feeds, ursodiol, metronidazole, and avoidance of excessive caloric provision * signed parent or legal guardian informed consent Exclusion Criteria: * Acute treatable infection (e.g. urinary tract infection, sepsis) * Known allergy to egg or fish protein * Contraindications to Omegaven * Pregnancy * Serum triglyceride level greater than 400 mg/dL at baseline * History of severe hemolytic disorders or INR greater than 1.5 at baseline (INR cutoff of greater than 2 for infants less than 1 week of age)

Locations (1)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.